haematology

News in brief: Jury still out on therapeutic heparin for COVID-19 patients; Rituximab biosimilars effective in DLBCL; Doctors in isolation due to schools COVID-19 cluster

Jury still out on therapeutic heparin for COVID-19 patients Therapeutic-dose heparin and LMWH do not improve outcomes in critically ill patients with COVID-19 but may be effective in patients with moderate illness, according to findings from three major studies. Published in the NEJM, the results from the ACTIV-4a, REMAP-CAP and ATTACC trials showed that in ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic